On Thursday, Intra-Cellular Therapies earned a positive adjustment to its Relative Strength (RS) Rating, from 80 to 83.
IBD's proprietary rating identifies share price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves.
Hone Your Stock-Picking Skills By Focusing On These Factors
Intra-Cellular Therapies is trading within a buy range after clearing an 82.00 buy point in a cup with handle. Once a stock moves 5% or higher beyond the original entry, it's considered out of buy range.
The company reported 0% earnings growth in the latest quarterly report. Sales gains came in at 39%.
Intra-Cellular Therapies holds the No. 40 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
